Calidi Biotherapeutics Receives Funding From The California Institute For Regenerative Medicine (Cirm) To Advance Supernova-1 And Neuronova-2 Development Programs
Round Type
Funding Round
San DiegoBiotechnologyHealth CareTherapeuticsDescription
Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic stem cell-based platforms to revolutionize oncolytic virus immunotherapies, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $3.1 million grant to support continued development of the company’s Supernova-1 (SNV1) pre-clinical program through Investigational New Drug (IND) application. In addition, CIRM has awarded City of Hope a $12 million grant to fund a Phase 1 physician-sponsored clinical trial evaluating Calidi’s licensed oncolytic virotherapy NeuroNova platform in patients with recurrent high-grade glioma, a form of advanced brain cancer.
Quick answer
Calidi Biotherapeutics raised an undisclosed amount in a Funding Round round, dated December 13, 2022. Calidi Biotherapeutics is based in San Diego, California, United States.
- How much did Calidi Biotherapeutics raise?
- Calidi Biotherapeutics raised an undisclosed amount in a Funding Round round on December 13, 2022.
- What does Calidi Biotherapeutics do?
- Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease.
- Where is Calidi Biotherapeutics based and how big is it?
- Calidi Biotherapeutics is based in San Diego, California, United States. Fundz records about 31 employees.
- Who are the decision-makers at Calidi Biotherapeutics?
- Fundz holds 1 contact at Calidi Biotherapeutics, including the CEO & Chair of the Board. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Calidi Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- Grey Wolf Therapeutics raised $49M (Funding Round) on January 27, 2023.
- Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
- ADARx Pharmaceuticals, Inc. raised $46M on January 26, 2023.
- HBM Alpha Therapeutics raised an undisclosed amount (Seed) on January 26, 2023.
- Apexigen raised $2.8M (Seed) on January 24, 2023.
- ADARx Pharmaceuticals, Inc. raised $46M (Funding Round) on January 20, 2023.
Who to call at Calidi Biotherapeutics, and when
A new round usually means Calidi Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Calidi Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Calidi Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Calidi Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Calidi Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Calidi Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.